Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Dividends Paid - Common (2020 - 2024)

Historic Dividends Paid - Common for Maravai Lifesciences Holdings (MRVI) over the last 5 years, with Q4 2024 value amounting to -$78000.0.

  • Maravai Lifesciences Holdings' Dividends Paid - Common changed N/A to -$78000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $494000.0, marking a year-over-year decrease of 1363.64%. This contributed to the annual value of $494000.0 for FY2024, which is 9485.79% down from last year.
  • As of Q4 2024, Maravai Lifesciences Holdings' Dividends Paid - Common stood at -$78000.0.
  • Over the past 5 years, Maravai Lifesciences Holdings' Dividends Paid - Common peaked at $119.7 million during Q4 2020, and registered a low of -$78000.0 during Q4 2024.
  • Moreover, its 5-year median value for Dividends Paid - Common was $30.9 million (2022), whereas its average is $28.9 million.
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' Dividends Paid - Common soared by 4096147.54% in 2021, and later crashed by 9693.58% in 2023.
  • Maravai Lifesciences Holdings' Dividends Paid - Common (Quarter) stood at $119.7 million in 2020, then tumbled by 60.61% to $47.2 million in 2021, then tumbled by 34.43% to $30.9 million in 2022, then plummeted by 95.78% to $1.3 million in 2023, then crashed by 105.98% to -$78000.0 in 2024.
  • Its Dividends Paid - Common was -$78000.0 in Q4 2024, compared to $572000.0 in Q2 2024 and $1.3 million in Q2 2023.